



## Hepatocellular Carcinoma: Epidemiology, Pathogenesis and Treatment

Guest Editors:

**Dr. Francesco Tovoli**

Dipartimento di Scienze Mediche  
e Chirurgiche, Alma Mater  
Studiorum Università di Bologna,  
Bologna, Italy

**Dr. Luca Ielasi**

Department of Medical and  
Surgical Sciences, University of  
Bologna, Bologna, Italy

Deadline for manuscript  
submissions:

**closed (30 November 2023)**

### Message from the Guest Editors

Dear Colleagues,

The topic of liver cancer is receiving increasing attention. Hepatocellular carcinomas are still the primary liver cancers, with the highest prevalence and death toll worldwide. Intrahepatic cholangiocarcinoma is also on the rise, and an ever-increasing number of rare liver cancers are being reported. Epidemiology, pathogenesis, and response to surgical, locoregional, and systemic treatments are all elements of particular interest which need further elucidation by future studies. This Special Issue will cover all aspects, and welcomes both original research and comprehensive review papers to guide a wide readership toward the most recent and ground-breaking research in this complex field.

Dr. Francesco Tovoli  
Dr. Luca Ielasi  
*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

**Journal Rank:** JCR - Q2 (*Oncology*)

## Contact Us

---

Current Oncology Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currnocol](http://mdpi.com/journal/currnocol)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)